Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab in Atopic Dermatitis
NCT05155085Phase 2Terminated
- Sponsor
- Allakos Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of lirentelimab in atopic dermatitis (AD), sponsored by Allakos Inc.. Started Jun 2022; status: terminated.
02
Drugs
lirentelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05155085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155085.